Details of the Drug

General Information of Drug (ID: DMUDIR8)

Drug Name

Fludrocortisone

Synonyms

fludrocortisone; Fluorocortisone; Fluorocortisol; Fluohydrisone; Florinef; Fluohydrocortisone; Astonin-H; Fludrocortone; Alflorone; Fludronef; Fludrone; Fluodrocortisone; 127-31-1; F-Cortef; 9alpha-Fluorocortisol; Fludrocortisona; Fludrocortisonum; F-COL; 9-Fluorocortisol; 9 alpha FF; 9-Fluorohydrocortisone; Cortisol, 9-fluoro-; StC 1400; 9alpha-Fludrocortisone; 9-AFH; 9-alpha-Fluorocortisol; 9-alpha-Fludrocortisone; Fludrocortisonum [INN-Latin]; Fludrocortisona [INN-Spanish]; 9-AF; Alflorone; Astonin; FCOL; Astonin H; Astonin Merck; Merck Brand of Fludrocortisone; U 5963; ZK5; F-Cortef;Florinef (TN); Fludrocortisone (INN); Fludrocortisone [INN:BAN]; Merck, Astonin; Astonin-H (TN); Hydrocortisone-9alpha-fluoro; Pregn-4-ene-3,20-dione, 9-fluoro-11beta,17,21-trihydroxy-(8CI); (11beta)-9-Fluoro-11,17,21-trihydroxypregn-4-ene-3,20-dione; (8S,9R,10S,11S,13S,14S,17R)-9-fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one; 9 Fluoro 17 Hydroxycortisone; 9 Fluorocortisol; 9 Fluorohydrocortisone; 9 alpha Fludrohydrocortisone; 9 alpha Fluoro 17 Hydroxycorticosterone; 9 alpha Fluorohydrocortisone; 9 alpha-Fludrocortisone; 9 alpha-Fluoro-17-Hydroxycorticosterone; 9 alpha-Fluorocortisol; 9 alpha-Fluorohydrocortisone; 9-Fluoro-11-beta,17,21-trihydroxypregn-4-ene-3,20-dione; 9-Fluoro-11beta,17,21-trihydroxypregn-4-ene-3,20-dione; 9-Fluoro-17-Hydroxycortisone; 9-alpha-Fluoro-17-hydroxycorticosterone; 9-alpha-Fluorohydrocortisone; 9alpha-Fluoro-11beta,17alpha,21-trihydroxy-4-pregnene-3,20-dione; 9alpha-Fluoro-17-hydroxycorticosterone; 9alpha-Fluorohydrocortisone; 9alpha-Fluoro-hydrocortisone

Indication

Disease Entry	ICD 11	Status	REF
Addison disease	5A74.0	Approved	[1]
Cerebral salt-wasting syndrome	5C72	Approved	[2]
Congenital adrenal hyperplasia	5A71.01	Approved	[1]
------------------------------------------------------------------------------------

Therapeutic Class

Antiinflammatory Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

380.4

Logarithm of the Partition Coefficient (xlogp)

1.7

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption AUC: The area under the plot of plasma concentration (AUC) of drug is 3.07 mcgh/L [3]
Absorption Cmax: The maximum plasma concentration (Cmax) of drug is 0.0012-0.20 mcg/L [3]
Absorption Tmax: The time to maximum plasma concentration (Tmax) is 0.5-2 h [3]
BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [4]
Clearance: The clearance of drug is 40.8 L/h [5]
Elimination: Approximately 80% of an administered dose of fludrocortisone shows up in the urine, with the other 20% likely eliminated via fecal or biliary route [3]
Half-life: The concentration or amount of drug in body reduced by one-half in 1 - 3.5 hours [6]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.00439 micromolar/kg/day [7]
Vd: The volume of distribution (Vd) of drug is 80-85 L [3]
Water Solubility: The ability of drug to dissolve in water is measured as 0.14 mg/mL [4]

Chemical Identifiers

Formula: C21H29FO5
IUPAC Name: (8S,9R,10S,11S,13S,14S,17R)-9-fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one
Canonical SMILES: C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@]2([C@H](C[C@]4([C@H]3CC[C@@]4(C(=O)CO)O)C)O)F
InChI: InChI=1S/C21H29FO5/c1-18-7-5-13(24)9-12(18)3-4-15-14-6-8-20(27,17(26)11-23)19(14,2)10-16(25)21(15,18)22/h9,14-16,23,25,27H,3-8,10-11H2,1-2H3/t14-,15-,16-,18-,19-,20-,21-/m0/s1
InChIKey: AAXVEMMRQDVLJB-BULBTXNYSA-N

Cross-matching ID

PubChem CID: 31378
ChEBI ID: CHEBI:50885
CAS Number: 127-31-1
DrugBank ID: DB00687
TTD ID: D0R7JT
INTEDE ID: DR0705
ACDINA ID: D00282

Combinatorial Drugs (CBD)

Click to Jump to the Detailed CBD Information of This Drug

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Androgen receptor (AR)	TTS64P2	ANDR_HUMAN	Inhibitor	[8]
Mineralocorticoid receptor (MR)	TT26PHO	MCR_HUMAN	Agonist	[9]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)_{Main DME}	DE4LYSA	CP3A4_HUMAN	Substrate	[10]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Antileukoproteinase (SLPI)	OTUNFUU8	SLPI_HUMAN	Gene/Protein Processing	[11]
Bone morphogenetic protein 6 (BMP6)	OT9WN536	BMP6_HUMAN	Gene/Protein Processing	[11]
C-C motif chemokine 2 (CCL2)	OTAD2HEL	CCL2_HUMAN	Gene/Protein Processing	[12]
C-C motif chemokine 3 (CCL3)	OTW2H3ND	CCL3_HUMAN	Gene/Protein Processing	[12]
C-C motif chemokine 4 (CCL4)	OT6B8P25	CCL4_HUMAN	Gene/Protein Processing	[12]
Cystine/glutamate transporter (SLC7A11)	OTKJ6PXW	XCT_HUMAN	Gene/Protein Processing	[11]
Hepatocyte growth factor receptor (MET)	OT7K55MU	MET_HUMAN	Gene/Protein Processing	[11]
Interleukin-1 alpha (IL1A)	OTPSGILV	IL1A_HUMAN	Gene/Protein Processing	[11]
Interleukin-1 beta (IL1B)	OT0DWXXB	IL1B_HUMAN	Gene/Protein Processing	[11]
Interleukin-8 (CXCL8)	OTS7T5VH	IL8_HUMAN	Gene/Protein Processing	[11]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Addison disease

ICD Disease Classification

5A74.0

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Androgen receptor (AR)	DTT	AR	2.13E-01	-0.07	-0.11
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	7.93E-02	-8.20E-02	-8.93E-01

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Fludrocortisone

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Conivaptan	DM1V329	Moderate	Decreased metabolism of Fludrocortisone caused by Conivaptan mediated inhibition of CYP450 enzyme.	Hypo-osmolality/hyponatraemia [5C72]	[13]
-----------

Coadministration of a Drug Treating the Disease Different from Fludrocortisone (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Sodium bicarbonate	DMMU6BJ	Minor	Decreased absorption of Fludrocortisone due to altered gastric pH caused by Sodium bicarbonate.	Acidosis [5C73]	[14]
Arn-509	DMT81LZ	Moderate	Increased metabolism of Fludrocortisone caused by Arn-509 mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[15]
Dronedarone	DMA8FS5	Major	Increased risk of ventricular arrhythmias by the combination of Fludrocortisone and Dronedarone.	Angina pectoris [BA40]	[16]
Methylphenobarbital	DMDSWAG	Moderate	Increased metabolism of Fludrocortisone caused by Methylphenobarbital mediated induction of CYP450 enzyme.	Anxiety disorder [6B00-6B0Z]	[17]
Posaconazole	DMUL5EW	Moderate	Decreased metabolism of Fludrocortisone caused by Posaconazole mediated inhibition of CYP450 enzyme.	Aspergillosis [1F20]	[13]
Levalbuterol	DM5YBO1	Minor	Increased risk of hypokalemia by the combination of Fludrocortisone and Levalbuterol.	Asthma [CA23]	[18]
Terbutaline	DMD4381	Minor	Increased risk of hypokalemia by the combination of Fludrocortisone and Terbutaline.	Asthma [CA23]	[13]
Pirbuterol	DMI5678	Minor	Increased risk of hypokalemia by the combination of Fludrocortisone and Pirbuterol.	Asthma [CA23]	[13]
Salbutamol	DMN9CWF	Minor	Increased risk of hypokalemia by the combination of Fludrocortisone and Salbutamol.	Asthma [CA23]	[18]
Roflumilast	DMPGHY8	Moderate	Additive immunosuppressive effects by the combination of Fludrocortisone and Roflumilast.	Asthma [CA23]	[15]
Ofloxacin	DM0VQN3	Major	Increased risk of tendinitis/tendon rupture by the combination of Fludrocortisone and Ofloxacin.	Bacterial infection [1A00-1C4Z]	[19]
Dalfopristin	DM4LTKV	Moderate	Decreased metabolism of Fludrocortisone caused by Dalfopristin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[20]
Clarithromycin	DM4M1SG	Moderate	Decreased metabolism of Fludrocortisone caused by Clarithromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[13]
Sparfloxacin	DMB4HCT	Major	Increased risk of tendinitis/tendon rupture by the combination of Fludrocortisone and Sparfloxacin.	Bacterial infection [1A00-1C4Z]	[19]
Gemifloxacin	DMHT34O	Major	Increased risk of tendinitis/tendon rupture by the combination of Fludrocortisone and Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[19]
Norfloxacin	DMIZ6W2	Major	Increased risk of tendinitis/tendon rupture by the combination of Fludrocortisone and Norfloxacin.	Bacterial infection [1A00-1C4Z]	[19]
ABT-492	DMJFD2I	Major	Increased risk of tendinitis/tendon rupture by the combination of Fludrocortisone and ABT-492.	Bacterial infection [1A00-1C4Z]	[19]
Levofloxacin	DMS60RB	Major	Increased risk of tendinitis/tendon rupture by the combination of Fludrocortisone and Levofloxacin.	Bacterial infection [1A00-1C4Z]	[19]
Lomefloxacin	DMVRH9C	Major	Increased risk of tendinitis/tendon rupture by the combination of Fludrocortisone and Lomefloxacin.	Bacterial infection [1A00-1C4Z]	[19]
Lapatinib	DM3BH1Y	Moderate	Decreased metabolism of Fludrocortisone caused by Lapatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[21]
Tucatinib	DMBESUA	Moderate	Decreased metabolism of Fludrocortisone caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[13]
Vilanterol	DMF5EK1	Minor	Increased risk of hypokalemia by the combination of Fludrocortisone and Vilanterol.	Chronic obstructive pulmonary disease [CA22]	[18]
Salmeterol	DMIEU69	Minor	Increased risk of hypokalemia by the combination of Fludrocortisone and Salmeterol.	Chronic obstructive pulmonary disease [CA22]	[13]
Indacaterol	DMQJHR7	Minor	Increased risk of hypokalemia by the combination of Fludrocortisone and Indacaterol.	Chronic obstructive pulmonary disease [CA22]	[13]
Arformoterol	DMYM974	Minor	Increased risk of hypokalemia by the combination of Fludrocortisone and Arformoterol.	Chronic obstructive pulmonary disease [CA22]	[13]
Phenylbutazone	DMAYL0T	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Fludrocortisone and Phenylbutazone.	Chronic pain [MG30]	[22]
Ketoprofen	DMRKXPT	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Fludrocortisone and Ketoprofen.	Chronic pain [MG30]	[22]
Isoproterenol	DMK7MEY	Minor	Increased risk of hypokalemia by the combination of Fludrocortisone and Isoproterenol.	Conduction disorder [BC63]	[18]
Mivacurium	DM473VD	Moderate	Additive neuromuscular blocking effects by the combination of Fludrocortisone and Mivacurium.	Corneal disease [9A76-9A78]	[13]
Pancuronium	DMB0VY8	Moderate	Additive neuromuscular blocking effects by the combination of Fludrocortisone and Pancuronium.	Corneal disease [9A76-9A78]	[13]
Tubocurarine	DMBZIVP	Moderate	Additive neuromuscular blocking effects by the combination of Fludrocortisone and Tubocurarine.	Corneal disease [9A76-9A78]	[13]
Mifepristone	DMGZQEF	Major	Decreased metabolism of Fludrocortisone caused by Mifepristone mediated inhibition of CYP450 enzyme.	Cushing syndrome [5A70]	[23]
Ivacaftor	DMZC1HS	Moderate	Decreased metabolism of Fludrocortisone caused by Ivacaftor mediated inhibition of CYP450 enzyme.	Cystic fibrosis [CA25]	[24]
MK-8228	DMOB58Q	Moderate	Decreased metabolism of Fludrocortisone caused by MK-8228 mediated inhibition of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[25]
Nefazodone	DM4ZS8M	Moderate	Decreased metabolism of Fludrocortisone caused by Nefazodone mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[13]
Primidone	DM0WX6I	Moderate	Increased metabolism of Fludrocortisone caused by Primidone mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[26]
Oxcarbazepine	DM5PU6O	Moderate	Increased metabolism of Fludrocortisone caused by Oxcarbazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[27]
Cenobamate	DM8KLU9	Moderate	Increased metabolism of Fludrocortisone caused by Cenobamate mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[28]
Fosphenytoin	DMOX3LB	Moderate	Increased metabolism of Fludrocortisone caused by Fosphenytoin mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[29]
Rufinamide	DMWE60C	Moderate	Increased metabolism of Fludrocortisone caused by Rufinamide mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[15]
Ethotoin	DMXWOCP	Moderate	Increased metabolism of Fludrocortisone caused by Ethotoin mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[29]
Phenobarbital	DMXZOCG	Moderate	Increased metabolism of Fludrocortisone caused by Phenobarbital mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[26]
Mefenamic acid	DMK7HFI	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Fludrocortisone and Mefenamic acid.	Female pelvic pain [GA34]	[22]
Tazemetostat	DMWP1BH	Moderate	Increased metabolism of Fludrocortisone caused by Tazemetostat mediated induction of CYP450 enzyme.	Follicular lymphoma [2A80]	[30]
Itraconazole	DMCR1MV	Moderate	Decreased metabolism of Fludrocortisone caused by Itraconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[13]
Ketoconazole	DMPZI3Q	Moderate	Decreased metabolism of Fludrocortisone caused by Ketoconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[13]
Boceprevir	DMBSHMF	Moderate	Decreased metabolism of Fludrocortisone caused by Boceprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[13]
Telaprevir	DMMRV29	Moderate	Decreased metabolism of Fludrocortisone caused by Telaprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[31]
Rifampin	DMA8J1G	Moderate	Increased metabolism of Fludrocortisone caused by Rifampin mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[32]
Rifapentine	DMCHV4I	Moderate	Increased metabolism of Fludrocortisone caused by Rifapentine mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[33]
Delavirdine	DM3NF5G	Moderate	Decreased metabolism of Fludrocortisone caused by Delavirdine mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[13]
Cobicistat	DM6L4H2	Moderate	Decreased metabolism of Fludrocortisone caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[13]
Saquinavir	DMG814N	Moderate	Decreased metabolism of Fludrocortisone caused by Saquinavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[13]
Etravirine	DMGV8QU	Moderate	Increased metabolism of Fludrocortisone caused by Etravirine mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[34]
Amprenavir	DMLMXE0	Moderate	Decreased metabolism of Fludrocortisone caused by Amprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[13]
Darunavir	DMN3GCH	Moderate	Decreased metabolism of Fludrocortisone caused by Darunavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[13]
Atazanavir	DMSYRBX	Moderate	Decreased metabolism of Fludrocortisone caused by Atazanavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[13]
Bempedoic acid	DM1CI9R	Major	Increased risk of tendinitis/tendon rupture by the combination of Fludrocortisone and Bempedoic acid.	Hyper-lipoproteinaemia [5C80]	[35]
Teriflunomide	DMQ2FKJ	Major	Additive immunosuppressive effects by the combination of Fludrocortisone and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[36]
Meclofenamic acid	DM05FXR	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Fludrocortisone and Meclofenamic acid.	Inflammatory spondyloarthritis [FA92]	[37]
Amobarbital	DM0GQ8N	Moderate	Increased metabolism of Fludrocortisone caused by Amobarbital mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[26]
Denosumab	DMNI0KO	Moderate	Additive immunosuppressive effects by the combination of Fludrocortisone and Denosumab.	Low bone mass disorder [FB83]	[38]
Ceritinib	DMB920Z	Moderate	Decreased metabolism of Fludrocortisone caused by Ceritinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[13]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Fludrocortisone caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[39]
Selpercatinib	DMZR15V	Moderate	Decreased metabolism of Fludrocortisone caused by Selpercatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[15]
Idelalisib	DM602WT	Moderate	Decreased metabolism of Fludrocortisone caused by Idelalisib mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[13]
IPI-145	DMWA24P	Moderate	Decreased metabolism of Fludrocortisone caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[40]
Arsenic trioxide	DM61TA4	Major	Increased risk of ventricular arrhythmias by the combination of Fludrocortisone and Arsenic trioxide.	Mature B-cell lymphoma [2A85]	[41]
Dabrafenib	DMX6OE3	Moderate	Increased metabolism of Fludrocortisone caused by Dabrafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[15]
Tecfidera	DM2OVDT	Moderate	Additive immunosuppressive effects by the combination of Fludrocortisone and Tecfidera.	Multiple sclerosis [8A40]	[42]
Fingolimod	DM5JVAN	Major	Additive immunosuppressive effects by the combination of Fludrocortisone and Fingolimod.	Multiple sclerosis [8A40]	[43]
Ocrelizumab	DMEZ2KH	Moderate	Additive immunosuppressive effects by the combination of Fludrocortisone and Ocrelizumab.	Multiple sclerosis [8A40]	[44]
Ozanimod	DMT6AM2	Major	Additive immunosuppressive effects by the combination of Fludrocortisone and Ozanimod.	Multiple sclerosis [8A40]	[15]
Fedratinib	DM4ZBK6	Moderate	Decreased metabolism of Fludrocortisone caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[13]
Nilotinib	DM7HXWT	Moderate	Decreased metabolism of Fludrocortisone caused by Nilotinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[45]
Dasatinib	DMJV2EK	Moderate	Decreased metabolism of Fludrocortisone caused by Dasatinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[46]
Omacetaxine mepesuccinate	DMPU2WX	Moderate	Additive immunosuppressive effects by the combination of Fludrocortisone and Omacetaxine mepesuccinate.	Myeloproliferative neoplasm [2A20]	[47]
Modafinil	DMYILBE	Minor	Increased metabolism of Fludrocortisone caused by Modafinil mediated induction of CYP450 enzyme.	Narcolepsy [7A20]	[48]
Bupropion	DM5PCS7	Major	Increased risk of lowers seizure threshold by the combination of Fludrocortisone and Bupropion.	Nicotine use disorder [6C4A]	[49]
Levomethadyl Acetate	DM06HG5	Major	Increased risk of ventricular arrhythmias by the combination of Fludrocortisone and Levomethadyl Acetate.	Opioid use disorder [6C43]	[50]
Naproxen	DMZ5RGV	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Fludrocortisone and Naproxen.	Osteoarthritis [FA00-FA05]	[22]
Rucaparib	DM9PVX8	Moderate	Decreased metabolism of Fludrocortisone caused by Rucaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[51]
Aspirin	DM672AH	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Fludrocortisone and Aspirin.	Pain [MG30-MG3Z]	[52]
Etodolac	DM6WJO9	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Fludrocortisone and Etodolac.	Pain [MG30-MG3Z]	[22]
Diflunisal	DM7EN8I	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Fludrocortisone and Diflunisal.	Pain [MG30-MG3Z]	[22]
Ibuprofen	DM8VCBE	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Fludrocortisone and Ibuprofen.	Pain [MG30-MG3Z]	[22]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Fludrocortisone caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[53]
Lefamulin	DME6G97	Moderate	Decreased metabolism of Fludrocortisone caused by Lefamulin mediated inhibition of CYP450 enzyme.	Pneumonia [CA40]	[54]
Choline salicylate	DM8P137	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Fludrocortisone and Choline salicylate.	Postoperative inflammation [1A00-CA43]	[55]
Lonafarnib	DMGM2Z6	Moderate	Decreased metabolism of Fludrocortisone caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[13]
Ritodrine	DM4V6RL	Minor	Increased risk of hypokalemia by the combination of Fludrocortisone and Ritodrine.	Preterm labour/delivery [JB00]	[13]
Temsirolimus	DMS104F	Moderate	Increased plasma concentrations of Fludrocortisone and Temsirolimus due to competitive inhibition of the same metabolic pathway.	Renal cell carcinoma [2C90]	[56]
Gatifloxacin	DMSL679	Major	Increased risk of tendinitis/tendon rupture by the combination of Fludrocortisone and Gatifloxacin.	Respiratory infection [CA07-CA4Z]	[19]
Salsalate	DM13P4C	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Fludrocortisone and Salsalate.	Rheumatoid arthritis [FA20]	[55]
Meloxicam	DM2AR7L	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Fludrocortisone and Meloxicam.	Rheumatoid arthritis [FA20]	[22]
Canakinumab	DM8HLO5	Moderate	Additive immunosuppressive effects by the combination of Fludrocortisone and Canakinumab.	Rheumatoid arthritis [FA20]	[57]
Oxaprozin	DM9UB0P	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Fludrocortisone and Oxaprozin.	Rheumatoid arthritis [FA20]	[22]
Rilonacept	DMGLUQS	Moderate	Additive immunosuppressive effects by the combination of Fludrocortisone and Rilonacept.	Rheumatoid arthritis [FA20]	[57]
Flurbiprofen	DMGN4BY	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Fludrocortisone and Flurbiprofen.	Rheumatoid arthritis [FA20]	[22]
Golimumab	DMHZV7X	Major	Additive immunosuppressive effects by the combination of Fludrocortisone and Golimumab.	Rheumatoid arthritis [FA20]	[58]
Leflunomide	DMR8ONJ	Major	Additive immunosuppressive effects by the combination of Fludrocortisone and Leflunomide.	Rheumatoid arthritis [FA20]	[36]
Trifluoperazine	DMKBYWI	Moderate	Increased risk of ventricular arrhythmias by the combination of Fludrocortisone and Trifluoperazine.	Schizophrenia [6A20]	[18]
Risperidone	DMN6DXL	Moderate	Increased risk of ventricular arrhythmias by the combination of Fludrocortisone and Risperidone.	Schizophrenia [6A20]	[18]
Amisulpride	DMSJVAM	Moderate	Increased risk of ventricular arrhythmias by the combination of Fludrocortisone and Amisulpride.	Schizophrenia [6A20]	[18]
Pimozide	DMW83TP	Major	Increased risk of ventricular arrhythmias by the combination of Fludrocortisone and Pimozide.	Schizophrenia [6A20]	[59]
Salicyclic acid	DM2F8XZ	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Fludrocortisone and Salicyclic acid.	Seborrhoeic dermatitis [EA81]	[52]
Anthrax vaccine	DM9GSWY	Moderate	Antagonize the effect of Fludrocortisone when combined with Anthrax vaccine.	Sepsis [1G40-1G41]	[60]
Voxelotor	DMCS6M5	Moderate	Decreased metabolism of Fludrocortisone caused by Voxelotor mediated inhibition of CYP450 enzyme.	Sickle-cell disorder [3A51]	[13]
Telotristat ethyl	DMDIYFZ	Moderate	Increased metabolism of Fludrocortisone caused by Telotristat ethyl mediated induction of CYP450 enzyme.	Small intestine developmental anomaly [DA90]	[15]
Larotrectinib	DM26CQR	Moderate	Decreased metabolism of Fludrocortisone caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[18]
Armodafinil	DMGB035	Minor	Increased metabolism of Fludrocortisone caused by Armodafinil mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[48]
LEE011	DMMX75K	Moderate	Decreased metabolism of Fludrocortisone caused by LEE011 mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[61]
Pitolisant	DM8RFNJ	Moderate	Increased metabolism of Fludrocortisone caused by Pitolisant mediated induction of CYP450 enzyme.	Somnolence [MG42]	[15]
Fostamatinib	DM6AUHV	Moderate	Decreased metabolism of Fludrocortisone caused by Fostamatinib mediated inhibition of CYP450 enzyme.	Thrombocytopenia [3B64]	[62]
Pipecuronium	DM5F84A	Moderate	Additive neuromuscular blocking effects by the combination of Fludrocortisone and Pipecuronium.	Tonus and reflex abnormality [MB47]	[13]
Doxacurium	DMKE7L9	Moderate	Additive neuromuscular blocking effects by the combination of Fludrocortisone and Doxacurium.	Tonus and reflex abnormality [MB47]	[13]
Vecuronium	DMP0UK2	Moderate	Additive neuromuscular blocking effects by the combination of Fludrocortisone and Vecuronium.	Tonus and reflex abnormality [MB47]	[13]
Rocuronium	DMY9BMK	Moderate	Additive neuromuscular blocking effects by the combination of Fludrocortisone and Rocuronium.	Tonus and reflex abnormality [MB47]	[13]
Sirolimus	DMGW1ID	Moderate	Increased plasma concentrations of Fludrocortisone and Sirolimus due to competitive inhibition of the same metabolic pathway.	Transplant rejection [NE84]	[56]
Tacrolimus	DMZ7XNQ	Moderate	Increased plasma concentrations of Fludrocortisone and Tacrolimus due to competitive inhibition of the same metabolic pathway.	Transplant rejection [NE84]	[56]
Cinoxacin	DM4EWNS	Major	Increased risk of tendinitis/tendon rupture by the combination of Fludrocortisone and Cinoxacin.	Urinary tract infection [GC08]	[19]
Nalidixic acid	DMRM0JV	Major	Increased risk of tendinitis/tendon rupture by the combination of Fludrocortisone and Nalidixic acid.	Urinary tract infection [GC08]	[19]
Amiodarone	DMUTEX3	Major	Increased risk of ventricular arrhythmias by the combination of Fludrocortisone and Amiodarone.	Ventricular tachyarrhythmia [BC71]	[63]
-----------


⏷ Show the Full List of 123 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Quinoline yellow WS	E00309	24671	Colorant
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Brushite	E00392	104805	Diluent
Calcium hydrogenphosphate	E00294	24441	Diluent
Carmellose sodium	E00625	Not Available	Disintegrant
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Cellulose microcrystalline	E00698	Not Available	Adsorbent; Suspending agent; Diluent
--------------------


⏷ Show the Full List of 9 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Fludrocortisone Acetate 0.1mg tablet	0.1mg	Tablet	Oral
Fludrocortisone 0.1 mg tablet	0.1 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	Fludrocortisone FDA Label
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2873).
3	UK Approved Drugs: Fludrocortisone
4	BDDCS applied to over 900 drugs
5	Hamitouche N, Comets E, Ribot M, Alvarez JC, Bellissant E, Laviolle B: Population Pharmacokinetic-Pharmacodynamic Model of Oral Fludrocortisone and Intravenous Hydrocortisone in Healthy Volunteers. AAPS J. 2017 May;19(3):727-735. doi: 10.1208/s12248-016-0041-9. Epub 2017 Jan 12.
6	MedSafe NZ: Florinef
7	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
8	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
9	Mineralocorticoid receptor-mediated inhibition of the hypothalamic-pituitary-adrenal axis in aged humans. J Gerontol A Biol Sci Med Sci. 2003 Oct;58(10):B900-5.
10	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
11	An in vitro coculture system of human peripheral blood mononuclear cells with hepatocellular carcinoma-derived cells for predicting drug-induced liver injury. Arch Toxicol. 2021 Jan;95(1):149-168. doi: 10.1007/s00204-020-02882-4. Epub 2020 Aug 20.
12	Cell-based and cytokine-directed chemical screen to identify potential anti-multiple myeloma agents. Leuk Res. 2010 Jul;34(7):917-24. doi: 10.1016/j.leukres.2009.12.002. Epub 2010 Feb 8.
13	Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
14	Albin H, Vincon G, Demotes-Mainard F, et al "Effect of aluminium phosphate on the bioavailability of cimetidine and prednisolone." Eur J Clin Pharmacol 26 (1984): 271-3. [PMID: 6723769]
15	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
16	Product Information. Multaq (dronedarone). sanofi-aventis , Bridgewater, NJ.
17	Brooks SM, Werk EE, Ackerman SJ, Sullivan I, Thrasher K "Adverse effects of phenobarbital on corticosteroid metabolism in patients with bronchial asthma." N Engl J Med 286 (1972): 1125-8. [PMID: 4553339]
18	Cerner Multum, Inc. "Australian Product Information.".
19	FDA. U.S. Food and Drug Administration "Information for Healthcare Professionals. Fluoroquinolone Antimicrobial Drugs. FDA Alert [7/8/2008].".
20	Product Information. Synercid (dalfopristin-quinupristin) Rhone-Poulenc Rorer, Collegeville, PA.
21	Product Information. Tykerb (lapatinib). Novartis Pharmaceuticals, East Hanover, NJ.
22	Buchman AL, Schwartz MR "Colonic ulceration associated with the systemic use of nonsteroidal antiinflammatory medication." J Clin Gastroenterol 22 (1996): 224-6. [PMID: 8724264]
23	Product Information. Korlym (mifepristone). Corcept Therapeutics Incorporated, Menlo Park, CA.
24	Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
25	Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
26	Bartoszek M, Brenner AM, Szefler SJ "Prednisolone and methylprednisolone kinetics in children receiving anticonvulsant therapy." Clin Pharmacol Ther 42 (1987): 424-32. [PMID: 3665340]
27	Product Information. Trileptal (oxcarbazepine) Novartis Pharmaceuticals, East Hanover, NJ.
28	Product Information. Xcopri (cenobamate). SK Life Science, Inc., Paramus, NJ.
29	Frey BM, Frey FJ "Phenytoin modulates the pharmacokinetics of prednisolone and the pharmacodynamics of prednisolone as assessed by the inhibition of the mixed lymphocyte reaction in humans." Eur J Clin Invest 14 (1984): 1-6. [PMID: 6230241]
30	Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
31	Product Information. Incivek (telaprevir). Vertex Pharmaceuticals, Cambridge, MA.
32	Kyriazopoulou V, Parparousi O, Vagenakis AG "Rifampicin-induced adrenal crisis in Addisonian patients receiving corticosteroid replacement therapy." J Clin Endocrinol Metab 59 (1984): 1204-6. [PMID: 6490796]
33	Product Information. Priftin (rifapentine). Hoechst Marion-Roussel Inc, Kansas City, MO.
34	Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
35	Product Information. Nexletol (bempedoic acid). Esperion Therapeutics, Ann Arbor, MI.
36	Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
37	Messer J, Reitman D, Sacks HS, et al "Association of adrenocorticosteroid therapy and peptic-ulcer disease." N Engl J Med 309 (1983): 21-4. [PMID: 6343871]
38	Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
39	Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
40	Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
41	Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
42	Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
43	Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
44	Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
45	Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
46	Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
47	Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
48	Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
49	Product Information. Wellbutrin XL (buPROPion). GlaxoSmithKline, Philadelphia, PA.
50	Cohen J "Long-term efficacy and safety of terazosin alone and in combination with other antihypertensive agents." Am Heart J 122 (1991): 919-25. [PMID: 1678923]
51	EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
52	Hansen RA, Tu W, Wang J, Ambuehl R, McDonald CJ, Murray MD "Risk of adverse gastrointestinal events from inhaled corticosteroids." Pharmacotherapy 28 (2008): 1325-34. [PMID: 18956992]
53	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
54	Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
55	Baer PA, Shore A, Ikeman RL "Transient fall in serum salicylate levels following intraarticular injection of steroid in patients with rheumatoid arthritis." Arthritis Rheum 30 (1987): 345-7. [PMID: 3566826]
56	Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
57	Product Information. Arcalyst (rilonacept). Regeneron Pharmaceuticals Inc, Tarrytown, NY.
58	Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
59	Product Information. Orap Tablets (pimozide). Gate Pharmaceuticals, Sellersville, PA.
60	CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]
61	DSouza DL, Levasseur LM, Nezamis J, Robbins DK, Simms L, Koch KM "Effect of alosetron on the pharmacokinetics of alprazolam." J Clin Pharmacol 41 (2001): 452-4. [PMID: 11304902]
62	Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
63	Antonelli D, Atar S, Freedberg NA, Rosenfeld T "Torsade de pointes in patients on chronic amiodarone treatment: contributing factors and drug interactions." Isr Med Assoc J 7 (2005): 163-5. [PMID: 15792261]